Outcome	O
measures	O

The	O
research	O
objective	O
of	O
this	O
study	O
was	O
the	O
assessment	O
of	O
potential	O
superiority	O
of	O
ARB	O
compared	O
to	O
KALETRA	O
on	O
management	O
of	O
patients	O
with	O
COVID	O
-	O
19	O
.	O

The	O
primary	O
outcome	O
was	O
duration	B-PrimaryOutcome
of	I-PrimaryOutcome
hospitalization	I-PrimaryOutcome
and	O
clinical	B-PrimaryOutcome
improvement	I-PrimaryOutcome
7	B-TimeFrame
days	I-TimeFrame
after	I-TimeFrame
admission	I-TimeFrame
.	O

The	O
criteria	O
of	O
improvement	O
were	O
relief	B-OutcomeDefinition
of	I-OutcomeDefinition
cough	I-OutcomeDefinition
,	I-OutcomeDefinition
dyspnea	I-OutcomeDefinition
,	I-OutcomeDefinition
and	I-OutcomeDefinition
fever	I-OutcomeDefinition
.	O

Time	B-OtherOutcome
to	I-OtherOutcome
relieving	I-OtherOutcome
fever	I-OtherOutcome
was	O
also	O
assessed	O
across	O
the	O
two	O
groups	O
.	O

The	O
secondary	O
outcomes	O
were	O
death	B-SecondaryOutcome
during	B-TimeFrame
the	I-TimeFrame
30	I-TimeFrame
days	I-TimeFrame
of	I-TimeFrame
treatment	I-TimeFrame
,	O
duration	B-SecondaryOutcome
of	I-SecondaryOutcome
hospitalization	I-SecondaryOutcome
,	O
changing	B-SecondaryOutcome
laboratory	I-SecondaryOutcome
tests	I-SecondaryOutcome
during	B-TimeFrame
7	I-TimeFrame
days	I-TimeFrame
,	O
changing	B-SecondaryOutcome
of	I-SecondaryOutcome
CT	I-SecondaryOutcome
findings	I-SecondaryOutcome
after	B-TimeFrame
30	I-TimeFrame
days	I-TimeFrame
,	O
and	O
the	O
need	B-SecondaryOutcome
for	I-SecondaryOutcome
invasive	I-SecondaryOutcome
mechanical	I-SecondaryOutcome
ventilation	I-SecondaryOutcome
.	O

We	O
documented	O
the	O
age	O
,	O
gender	O
,	O
job	O
,	O
education	O
status	O
,	O
underlying	O
disease	O
(	O
history	O
of	O
diabetes	O
,	O
ischemic	O
heart	O
disease	O
,	O
hypertension	O
,	O
asthma	O
,	O
)	O
and	O
smoking	O
status	O
,	O
as	O
demographic	O
variables	O
.	O

Fever	B-OtherOutcome
,	O
cough	B-OtherOutcome
,	O
dyspnea	B-OtherOutcome
,	O
nausea	B-OtherOutcome
and	I-OtherOutcome
vomiting	I-OtherOutcome
,	O
diarrhea	B-OtherOutcome
,	O
fatigue	B-OtherOutcome
and	I-OtherOutcome
weakness	I-OtherOutcome
,	O
loss	B-OtherOutcome
of	I-OtherOutcome
appetite	I-OtherOutcome
,	O
and	O
taste	B-OtherOutcome
were	O
also	O
documented	O
at	B-TimeFrame
the	I-TimeFrame
first	I-TimeFrame
day	I-TimeFrame
of	I-TimeFrame
admission	I-TimeFrame
.	O

The	O
saturation	B-OtherOutcome
of	I-OtherOutcome
peripheral	I-OtherOutcome
oxygen	I-OtherOutcome
,	O
C	B-OtherOutcome
-	I-OtherOutcome
reactive	I-OtherOutcome
protein	I-OtherOutcome
(	I-OtherOutcome
CRP	I-OtherOutcome
)	I-OtherOutcome
,	O
complete	B-OtherOutcome
blood	I-OtherOutcome
cell	I-OtherOutcome
count	I-OtherOutcome
(	I-OtherOutcome
CBC	I-OtherOutcome
)	I-OtherOutcome
,	O
erythrocyte	B-OtherOutcome
sedimentation	I-OtherOutcome
rate	I-OtherOutcome
(	I-OtherOutcome
ESR	I-OtherOutcome
)	I-OtherOutcome
,	O
aspartate	B-OtherOutcome
transaminase	I-OtherOutcome
(	I-OtherOutcome
AST	I-OtherOutcome
)	I-OtherOutcome
,	O
alanine	B-OtherOutcome
aminotransferase	I-OtherOutcome
(	I-OtherOutcome
ALT	I-OtherOutcome
)	I-OtherOutcome
,	O
white	B-OtherOutcome
blood	I-OtherOutcome
cell	I-OtherOutcome
count	I-OtherOutcome
(	I-OtherOutcome
WBC	I-OtherOutcome
)	I-OtherOutcome
,	O
lymphocyte	B-OtherOutcome
and	I-OtherOutcome
neutrophil	I-OtherOutcome
count	I-OtherOutcome
,	O
neutrophil	B-OtherOutcome
lymphocyte	I-OtherOutcome
ratio	I-OtherOutcome
,	O
total	B-OtherOutcome
bilirubin	I-OtherOutcome
,	O
blood	B-OtherOutcome
Na	I-OtherOutcome
and	I-OtherOutcome
K	I-OtherOutcome
,	O
creatinine	B-OtherOutcome
and	O
thyroid	B-OtherOutcome
stimulating	I-OtherOutcome
hormone	I-OtherOutcome
(	I-OtherOutcome
TSH	I-OtherOutcome
)	I-OtherOutcome
were	O
measured	O
at	B-TimeFrame
the	I-TimeFrame
first	I-TimeFrame
day	I-TimeFrame
of	I-TimeFrame
admission	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
days	I-TimeFrame
after	I-TimeFrame
.	O

The	O
CT	B-OtherOutcome
scan	I-OtherOutcome
and	O
chest	B-OtherOutcome
X	I-OtherOutcome
-	I-OtherOutcome
ray	I-OtherOutcome
were	O
taken	O
at	B-TimeFrame
the	I-TimeFrame
first	I-TimeFrame
day	I-TimeFrame
of	I-TimeFrame
admission	I-TimeFrame
and	I-TimeFrame
30	I-TimeFrame
days	I-TimeFrame
after	I-TimeFrame
.	O

The	O
PCR	B-OtherOutcome
test	I-OtherOutcome
was	O
taken	O
at	B-TimeFrame
admission	I-TimeFrame
and	I-TimeFrame
the	I-TimeFrame
time	I-TimeFrame
of	I-TimeFrame
discharge	I-TimeFrame
.	O

We	O
considered	O
the	O
following	O
criteria	O
for	O
discharge	O
from	O
hospital	O
:	O
Resolution	O
of	O
fever	O
at	O
least	O
for	O
72	O
h	O
and	O
decreasing	O
trend	O
in	O
LDH	O
and	O
CRP	O
and	O
lymphocytosis	O
significant	O
and	O
having	O
normal	O
saturation	O
of	O
peripheral	O
oxygen	O
.	O

We	O
categorized	O
the	O
patients	O
to	O
three	O
groups	O
based	O
on	O
severity	O
of	O
disease	O
according	O
to	O
the	O
CT	O
scan	O
and	O
chest	O
X	O
-	O
ray	O
findings	O
.	O

Mild	O
,	O
moderate	O
and	O
severe	O
categories	O
were	O
defined	O
as	O
involvement	O
of	O
base	O
,	O
less	O
and	O
more	O
than	O
50	O
%	O
of	O
the	O
lung	O
field	O
respectively	O
in	O
CXR	O
and	O
CT	O
scan	O
.	O

